Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × Loratadine × Clear all

Phase

Phase EARLY_PHASE1 2 Phase NA 1 Phase 4 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphangioleiomyomatosis 1

Interventions

Cisplatin 909 Cyclophosphamide 865 Carboplatin 851 Radiotherapy 798 Bevacizumab 752 Gemcitabine 722 pembrolizumab 671 Docetaxel 666 Paclitaxel 660 Oxaliplatin 622 Capecitabine 578 Fluorouracil 515 Rituximab 509 Nivolumab 448 Dexamethasone 440 Etoposide 416 Doxorubicin 412 Irinotecan 398 Leucovorin 342 Drug Therapy 342 Cytarabine 305 Cetuximab 298 Lenalidomide 292 Pemetrexed 287 Trastuzumab 286 durvalumab 271 Filgrastim 254 Prednisone 250 Magnetic Resonance Spectroscopy 244 Temozolomide 239

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05190627 2022-01-27

LORALAM

Institut d'Investigació Biomèdica de Bellvitge

Phase 2 Unknown

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡